Vitamin B12 and ageing: Current issues and interaction with folate

Annals of Clinical Biochemistry

Volumn 50, Issue 4, 2013, Pages 315-329

  Hughes, Catherine F ^a   Ward, Mary ^a   Hoey, Leane ^a   McNulty, Helene ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Ageing; Folate; Holotranscobalamin

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; BIOLOGICAL MARKER; HOLOTRANSCOBALAMIN;

AGING; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CYANOCOBALAMIN DEFICIENCY; DEMENTIA; DIETARY INTAKE; GOLD STANDARD; HUMAN; MEGALOBLASTIC ANEMIA; NERVE INJURY; NUTRITIONAL STATUS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DIET THERAPY; METABOLISM; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; STANDARDS; B12 ABSORPTION; METHODOLOGY; PSYCHOLOGICAL ASPECT; STANDARD;

AGING; ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; FOLIC ACID; FOOD, FORTIFIED; HUMANS; METABOLIC NETWORKS AND PATHWAYS; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

AGEING; B12 ABSORPTION; FOLATE; HOLOTRANSCOBALAMIN; VITAMIN B12;

EID: 84890236668     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563212473279     Document Type: Review

References (127)

1. Scott JM. Folate (folic acid) and vitamin B 12. In: Garrow JS, James WPT and Ralph A (eds) Human Nutrition and Dietetics, 10th edn. London: Churchill Livingstone, 2003, pp.271-80.
2. 12 interrelationships; links to disease risk. In: Bailey LB (ed.) Folate in Health and Disease, 2nd edn. Boca Raton: CRC Press, 2010, pp.381-408.
3. 12 inter-relationships. Essays Biochem 1994; 28: 63-72.
4. Shane B. Folate chemistry and metabolism. In: Bailey LB (ed.) Folate in Health and Disease, 2nd edn. Boca Raton: CRC Press, 2010, pp.1-24.
5. Carmel R, Green R, Rosenblatt DS and Watkins D. Update on cobalamin, folate, and homocysteine. Hematology 2003; 1: 62-81.
6. Scott JM. Bioavailability of vitamin B 12. Eur J Clin Nutr 1997; 51(Suppl. 1): S49-53.
7. 12 without intrinsic factor. Acta Med Scand 1968; 184: 247-58.
8. Nexo E and Hoffmann-Lü cke E. Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility. Am J Clin Nutr 2011; 94: 359S-65S.
9. Chanarin I. The Megaloblastic Anaemias, 2nd edn. Oxford: Blackwell Scientific, 1979.
10. Carmel R. Cobalamin deficiency. In: Carmel R and Jacobsen DW (eds) Homocysteine in Health and Disease. Cambridge: Cambridge University Press, 2001, pp.289-305.
11. Carmel R. Cobalamin, the stomach, and aging. Am J Clin Nutr 1997; 66: 750-9.
12. 12 status and for monitoring the efficacy of intervention strategies. Food Nutr Bull 2008; 29: s52-63.
13. Gibson RS. Principles of Nutritional Assessment, 2nd edn. New York: Oxford University Press, 2005.
14. 12) handling. Implications for therapy. Drugs Aging 1998; 12: 277-92.
15. Briddon A. Homocysteine in the context of cobalamin metabolism and deficiency states. Amino Acids 2003; 24: 1-12.
16. Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP and Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60: 2-11.
17. Lindenbaum J, Savage DG, Stabler SP and Allen RH. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol 1990; 34: 99-107.
18. 12) deficiency and its application. J Nutr Health Aging 2011; 15: 227-31.
19. 12 deficiency: a dose-finding trial. Arch Intern Med 2005; 165: 1167-72.
20. Homocysteine Lowering Trialists Collaboration. Dosedependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82: 806-12.
21. McKinley MC, McNulty H, McPartlin J, et al. Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr 2001; 73: 759-64.
22. McNulty H, Dowey le RC, Strain JJ, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism. Circulation 2006; 113: 74-80.
23. 12 in reduction of risk of vascular disease. Lancet 2002; 359: 227-8.
24. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50: 3-32.
25. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
26. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A and Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1764-79.
27. Savage DG, Lindenbaum J, Stabler SP and Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994; 96: 239-46.
28. Rasmussen K. Studies of methylmalonic acid in humans. I. Concentrations in serum and urinary excretion in normal subjects after feeding and during fasting, and after loading with protein, fat, sugar, isoleucine, and valine. Clin Chem 1989; 35: 2271-6.
29. 12 deficiency - an update. Haematologica 2006; 91: 1506-12.
30. Herbert V. Staging vitamin B-12 (cobalamin) status in vegetarians. Am J Clin Nutr 1994; 59: 1213S-22S.
31. Herrmann W, Schorr H, Obeid R and Geisel J. Vitamin B-12 status, particularly holotranscobalamin II and methylmalonic acid concentrations, and hyperhomocysteinemia in vegetarians. Am J Clin Nutr 2003; 78: 131-6.
32. Miller JW. Assessing the association between vitamin B-12 status and cognitive function in older adults. Am J Clin Nutr 2006; 84: 1259-60.
33. 12 status in the elderly. Clin Chem 2011; 57: 856-63.
34. Hvas AM and Nexo E. Holotranscobalamin-a first choice assay for diagnosing early vitamin B deficiency? J Intern Med 2005; 257: 289-98.
35. 12 deficiency. Clin Chem 2006; 52: 278-85.
36. Lindgren A, Kilander A, Bagge E and Nexø E. Holotranscobalamin - a sensitive marker of cobalamin malabsorption. Eur J Clin Invest 1999; 29: 321-9.
37. Refsum H, Johnston C, Guttormsen AB and Nexo E. Holotranscobalamin and total transcobalamin in human plasma: determination, determinants, and reference values in healthy adults. Clin Chem 2006; 52: 129-37.
38. 12 absorption better than does serum vitamin B 12. Clin Chem 2004; 50: 1043-9.
39. von Castel-Roberts KM, Morkbak AL, Nexo E, et al. Holo-transcobalamin is an indicator of vitamin B-12 absorption in healthy adults with adequate vitamin B-12 status. Am J Clin Nutr 2007; 85: 1057-61.
40. 12) metabolism: emerging concepts in pathophysiology, diagnosis and treatment. Blood Rev 2007; 21: 113-30.
41. 12 and their association with homocysteine and cardiovascular disease in European populations. Eur J Clin Nutr 2009; 63: 18-30.
42. Finch S, Doyle W, Lowe C, et al. National Diet and Nutrition Survey: People Aged 65 Years and Over. Volume 1: Report of the Diet and Nutrition Survey. London: TSO, 1998.
43. Scott JM. Folate and vitamin B 12. Proc Nutr Soc 1999; 58: 441-8.
44. Carmel R. Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II. Am J Clin Nutr 2011; 94: 348S-58S.
45. Hathcock JN and Troendle GJ. Oral cobalamin for treatment of pernicious anemia? JAMA 1991; 265: 96-7.
46. van Asselt DZ, de Groot LC, van Staveren WA, et al. Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr 1998; 68: 328-34.
47. Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994; 35: 23-6.
48. Carmel R, Perez-Oerez G and Blaser M. Helicobacter pylori infection and food-cobalamin malabsorption. Dig Dis Sci 1994; 39: 309-14.
49. Jain K, Shah A, Bariwal J, et al. Recent advances in proton pump inhibitors and management of acid-peptic disorders. Bioorg Med Chem 2007; 15: 1181-205.
50. Richter JE, Peura D, Benjamin SB, Joelsson B and Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160: 1810-6.
51. Mitchell SL and Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. J Clin Epidemiol 2001; 54: 531-4.
52. 12). Ann Intern Med 1994; 120: 211-5.
53. 12 absorption. J Am Coll Nutr 1994; 13: 584-91.
54. 12 levels in patients with Zollinger-Ellison Syndrome. Am J Med 1998; 104: 422-30.
55. 12 status in older adults? JAMDA 2008; 9: 162-7.
56. 12 status in elderly individuals. Aliment Pharmacol Ther 2008; 27: 491-7.
57. Forgacs I and Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2-3.
58. McNulty H, Strain JJ, Pentieva K and Ward M. Onecarbon metabolism and cardiovascular disease outcomes in older adults. Proc Nutr Soc 2012; 71: 213-21.
59. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C!T polymorphism and risk of coronary heart disease: a metaanalysis. JAMA 2002; 288: 2023-31.
60. Lewis SJ, Ebrahim S and Smith GD. Meta-analysis of MTHFR 677C {combining right arrow} T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005; 331: 1053-58.
61. Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011; 378: 584-94.
62. 12 cellular delivery in healthy adult populations. Clin Biochem 2010; 43: 645-9.
63. von Castel-Dunwoody KM, Kauwell GPA, Shelnutt KP, et al. Transcobalamin 776C {combining right arrow} G polymorphism negatively affects vitamin B-12 metabolism. Am J Clin Nutr 2005; 81: 1436-41.
64. Healton EB, Brust JC, Garrett TJ and Lindenbaum J. Neurologic aspects of coabalmin deficiency. Medicine 1991; 70: 229-45.
65. 12) deficiency. Blood 2008; 112: 2214-21.
66. Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP and Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998; 92: 1191-8.
67. 12 deficiency. Haematologica 2008; 93: 1755-8.
68. Carmel R. Current concepts in cobalamin deficiency. Annu Rev Med 2000; 51: 357-75.
69. 12, Pantothenic Acid, Biotin and CholineWashington DC: National Academy Press, 1998, pp.306-56.
70. 12 related variables in Danish postmenopausal women. Am J Clin Nutr 2006; 83: 52-8.
71. Vogiatzoglou A, Smith AD, Nurk E, et al. Dietary sources of vitamin B-12 and their association with plasma vitamin B-12 concentrations in the general population: the Hordaland Homocysteine Study. Am J Clin Nutr 2009; 89: 1078-87.
72. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969; 56: 111-28.
73. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-22.
74. Wald DS, Law M and Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202-8.
75. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369: 1876-82.
76. 12, and serum total homocysteine levels in confirmed Alzheimer Disease. Arch Neurol 1998; 55: 1449-55.
77. 12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 2005; 20: 921-9.
78. Gjesdal CG, Vollset SE, Ueland PM, et al. Plasma total homocysteine level and bone mineral density: the Hordaland homocysteine study. Ann Intern Med 2006; 166: 88-94.
79. Clarke R, Birks J, Nexo E, et al. Low vitamin B-12 status and risk of cognitive decline in older adults. Am J Clin Nutr 2007; 86: 1384-91.
80. Lee M, Hong KS, Chang SC and Saver JL. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke 2010; 41: 1205-12.
81. Spence JD, Bang H, Chambless LE and Stampfer MJ. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 2005; 36: 2404-9.
82. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-600.
83. 12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002; 288: 973-9.
84. Bleie O, Strand E, Ueland PM, et al. Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B 12. Coron Artery Dis 2011; 22: 270-8.
85. 12 a cardiovascular and diabetes risk factor? A systematic review of cohort studies. Eur J Nutr 2011; 50: 97-106.
86. Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull 2008; 29(2 suppl): s143-72.
87. McCaddon A, Davies G, Hudson P, Tandy S and Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998; 13: 235-9.
88. Herrmann W and Obeid R. Biomarkers of neurodegenerative diseases. Clin Chem Lab Med 2011; 49: 343-4.
89. Wald DS, Kasturiratne A and Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement 2011; 7: 412-7.
90. Nurk E, Refsum H, Tell GS, et al. Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine study. Ann Neurol 2005; 58: 847-57.
91. 12 or homocysteine, is associated with dementia in elderly Latinos. J Nutr Health Aging 2005; 9: 39-43.
92. Mooijaart SP, Gussekloo J, Frolich M, et al. Homocysteine, vitamin B-12, and folic acid and the risk of cognitive decline in old age: the Leiden 85-Plus Study. Am J Clin Nutr 2005; 82: 866-71.
93. Tettamanti M, Garri MT, Nobili A, Riva E and Lucca U. Low folate and the risk of cognitive and functional deficits in the very old: the Monzino 80-plus Study. J Am Coll Nutr 2006; 25: 502-8.
94. McCracken C, Hudson P, Ellis R and McCaddon A. Medical Research Council Cognitive Function and Ageing Study. Methylmalonic acid and cognitive function in the Medical Research Council Cognitive Function and Ageing Study. Am J Clin Nutr 2006; 84: 1406-11.
95. Wald DS, Kasturiratne A and Simmonds M. Effect of folic acid, with or without other B vitamins, on cognitive decline: meta-analysis of randomized trials. Am J Med 2010; 123: 522-7.
96. Kang JH, Cook N, Manson J, Buring JE, Albert CM and Grodstein F. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr 2008; 88: 1602-10.
97. Brady CB, Gaziano JM, Cxypoliski RA, et al. Homocysteine lowering and cognition in CKD: the Veterans Affairs Homocysteine study. Am J Kidney Dis 2009; 54: 440-9.
98. Ford A, Flicker L, McCaul K, et al. The B-VITAGE trial: A randomized trial of homocysteine lowering treatment of depression in later life. Trials 2010; 11: 8.
99. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S and Galan P. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. Am J Clin Nutr 2011; 94: 278-86
100. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 2010; 5: e12244.
101. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI and Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006; 354: 2764-72.
102. Durga J, van Boxtel MPJ, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 2007; 369: 208-16.
103. Walker JG, Batterham PJ, Mackinnon AJ, et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms - the Beyond Ageing Project: a randomized controlled trial. Am J Clin Nutr 2012; 95: 194-203.
104. de Jager CA, Oulhaj A, Jacoby R, Refsum H and Smith AD. Cognitive and clinical outcomes of homocysteine- lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psych 2012; 27: 592-600.
105. 12 and folic acid levels as therapeutic target in preserving bone mineral density (BMD) of older men. Arch Gerontol Geriat 2012; 54: 469-72.
106. Dhonukshe-Rutten RA, Lips M, de Jong N, et al. Vitamin B-12 status is associated with bone mineral content and bone mineral density in frail elderly women but not in men. J Nutr 2003; 133: 801-7.
107. McLean RR, Jacques PF, Selhub J and Tucker KL. Homocysteine as a predictive factor for hip fracture in older persons. New Engl J Med 2004; 350: 2042-9.
108. Morris MS, Jacques PF and Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005; 37: 234-42.
109. 12 is associated with lower BMD: the Framingham Osteoporosis study. J Bone Miner Res 2005; 20: 152-8.
110. Goerss JB, Kim CH, Atkinson EJ, Eastell R, O'Fallon M and Melton LJ. Risk of fractures in patients with pernicious anemia. J Bone Miner Res 1992; 7: 573-9.
111. 12 and etidronate therapy in a patient with pernicious anemia. Metabolism 1994; 43: 468-9.
112. Stone KL, Bauer DC, Sellmeyer D and Cummings SR. Low serum vitamin B-12 levels are associated with increased hip bone loss in older women: a prospective study. Clin Endocrinol Metab 2004; 89: 1217-21.
113. Green TJ, McMahon JA, Skeaff CM, Williams SM and Whiting SJ. Lowering homocysteine with B vitamins has no effect on biomarkers of bone turnover in older persons: a 2-y randomized controlled trial. Am J Clin Nutr 2007; 85: 460-4.
114. Herrmann M, Umanskaya N, Traber L, et al. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial. Clin Chem Lab Med 2007; 45: 1785-92.
115. Sato Y, Honda Y, Iwamoto J, Kanoko T and Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005; 293: 1082-8.
116. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD and Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001; 285: 2981-6.
117. Yang Q, Botto LD, Erickson JD, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006; 113: 1335-43.
118. 12, folic acid, and the nervous system. Lancet Neuro 2006; 5: 949-60.
119. Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J and Sampson EJ. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr 2005; 82: 442-50.
120. Troen AM, Mitchell B, Sorensen B, et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr 2006; 136: 189-94.
121. Mills JL, Von Kohorn I, Conley MR, et al. Low vitamin B-12 concentrations in patients without anemia: the effect of folic acid fortification of grain. Am J Clin Nutr 2003; 77: 1474-7.
122. 12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. Proc Natl Acad Sci USA 2007; 104: 19995-20000.
123. Morris MS, Jacques PF, Rosenberg IH and Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 2007; 85: 193-200.
124. 12 status in relation to cognitive impairment and anaemia in the setting of voluntary fortification in the UK. Br J Nutr 2008; 100: 1054-9.
125. Mills JL, Carter TC, Scott JM, et al. Do high blood folate concentrations exacerbate metabolic abnormalities in people with low vitamin B-12 status? Am J Clin Nutr 2011; 94: 495-500.
126. Mason JB. Folate consumption and cancer risk: a confirmation and some reassurance, but we're not out of the woods quite yet. Am J Cin Nutr 2011; 94: 936-64.
127. 12 (cobalamin) deficiency in elderly patients. CMAJ 2004; 171: 251-9.